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ABSTRACT
EXAMINATION OF SIGNALS INVOLVED IN DEXAMETHASONE INDUCED
APOPTOSIS IN NB2 LYMPHOMA CELLS
By Suhas Badarinath, B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University. Virginia Commonwealth University,

1999.

Director: Raphael J. Witorsch, Ph.D.
Professor
Department of Physiology

Consistent with previous studies, we demonstrated that dexamethasone (Dex)
caused cytolysis/apoptosis in log phase Nb2 lymphoma cells, while prolactin (Prl)
inhibited this effect. The Nb2 model was used to investigate the mechanisms of
apoptosis control with the aid of immunocytochemistry (ICC). We established with
absorption the specificity of staining due to Fas, Fas Ligand, Bcl-2, and Bax antibodies
(the specificity of anti-p53 could not be verified). Dex-induced cytolysis/apoptosis was
detected in synchronized (GofG1) cells after 6 and 8 hours of Dex exposure. A novel,
computerized technique was used to quantitate the proportion of cells immunostained for
the signals of interest in Nb2 cells in log phase and GofG, after up to 8 hours of Dex
exposure. We observed Fas, Fas Ligand, Bcl-2, Bax, and p53 in high proportions (72%86%) of log phase Nb2 cells. Neither synchrony in GofG1 nor exposure of synchronized

X

cells to Dex for up to 8 hours altered the proportion of immunostained cells. This study
has raised provocative issues regarding the resistance of Nb2 cells to Fas mediated
apoptosis, the phenotype of the p53 protein in Nb2 cells, and the possible interaction of
various signals that modulate apoptosis.

Chapter 1
Introduction

Cells mainly die by the processes of apoptosis and necrosis (Kiess and Gallaher,

1998; Ameisen, 1996; Barinaga, 1996; Lavin and Watters, 1993; Mihich and Schimke,
1994; Milas et al., 1994; Sen, 1992; Steller, 1995; Thomson, 1995; Tomei and Cope,
1994). The word apoptosis was used by Wylie in 1980 to describe a stereotyped mode of
cell death (Gottlieb and Babior, 1997; Wyllie et al., 1980). Currently, 'apoptosis'
encompasses a distinct set of morphological and biochemical events that characterize a
specific type of cell death (MacFarlane et al., 1996; Kerr et al., 1972; Wyllie et al., 1984;
Arends et al., 1990).
Early morphological changes associated with apoptosis involve compaction of
chromatin and its movement in segregated masses. The cytoplasm condenses as the cell
surface and nuclear outline become convoluted (Kiess and Gallaher, 1998; Ameisen,

1996; Lavin and Watters, 1993; Mihich and Schimke, 1994; Sen, 1992). Next, the
nucleus fragments while protrusions, or blebs, form on the cell surface. These surface
convolutions separate from the cell, become enveloped by membrane, and are released
into the extracellular fluid. The membrane bound vesicles, named apoptotic bodies,
contain fragmented DNA and intact cytoplasmic organelles. An increase in cell surface
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phosphatidyl serine and integrin signals digestion of apoptotic bodies by mononuclear
phagocytes. Ultimately, apoptosis kills the cell while keeping its contents separate from
adjacent tissues (Gottlieb and Babior, 1997). Many structural changes related to
apoptosis may be visualized. Nuclear DNA is fragmented into 200 base pair segments
and appears as a ladder pattern when subjected to gel electrophoresis (Gottlieb and
Babior, 1997). Although this nucleosomal pattern is common, apoptosis can occur
devoid of DNA laddering (Gottlieb and Babior, 1997; Schulze-Osthoff et al., 1994).
Apoptotic bodies may be viewed by light microscopy (Kiess and Gallaher, 1998; Sen,

1992; Tomei andCope, 1994), whereas other morphological changes such as the
condensation of chromatin and the compaction of cytoplasm require electron microscopy
(Gavrieli et al., 1992).
Biochemical and molecular changes accompany the morphological changes
involved in apoptosis. A change inCa

2+

concentration may be necessary for nuclease

cleavage of DNA (Kiess and Gallaher, 1998; Nicotera and Rossi, 1994). Indeed, aCa

-

Mg

2+

2+

sensitive endonuclease was found to cleave double stranded DNA between

nucleosomes (Kiess and Gallaher, 1998; Galli et al., 1995). The transcription and
translation of certain genes into proteins is an additional molecular event involved in
apoptosis (Kiess and Gallaher, 1998; Thompson, 1995; Tomei andCope, 1994). Certain
proteins have been shown to modulate elements of the apoptotic pathway in their
regulation, catalysis, and degradation (Kiess and Gallaher, 1998). In fact, inhibition of
protein synthesis was seen to halt or delay apoptosis (Kiess and Gallaher, 1998).
The killing of specific cells by apoptosis is central to many biological processes
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since it allows for cell renewal and histological regulation (Kiess and Gallaher, 1998).
Embryogenesis, for instance, relies upon targeted cell death for proper development. In
mammals, apoptosis is crucial for the development of gut mucosa and retina, and for the
regression of interdigital webs (Kiess and Gallaher, 1998; Haanen and Vermes, 1996). In
immune tolerance development, B and T lymphocytes recogillzing self-antigen are
eliminated by apoptosis (Gottlieb and Babior, 1997; Pircher et al., 1992). During aging,
lowered hormone levels lead to an atrophy of hormone sensitive tissue that is mediated
by apoptosis (Gottlieb and Babior, 1997; Kiplesund et al, 1988). Cells containing DNA
damage or viral infection are induced to die by apoptosis, the latter of which may be
caused by interaction with cytotoxic T lymphocytes (Kiess and Gallaher, 1998; Le Deist
et al., 1996; Migliorati et al., 1994) . Finally, autoimmune diabetes and thyroid disease
may be caused by the improper induction of pancreatic and thyroid cells into apoptosis
(Kiess and Gallaher, Lavin and Watters, 1993; Mihich and Schimke, 1994; Tomei and
Cope, 1994).
Regulation of apoptosis may be environmental or developmental (Desai and
Gruber, 1999). Environmental agents that elicit apoptosis invariably cause nonspecific
cellular damage. Examples of such stimuli include chemotherapeutic agents (Gottlieb
and Babior, 1997; D'Amico and McKenna, 1994), ultraviolet radiation (Gottlieb and
Babior, 1997; Gillardon et al., 1994), oxidizing agents (Gottlieb and Babior, 1997;
McConkey et al., 1988), and reperfusion injury (Gottlieb and Babior, 1997, 1994).
Developmental regulation of cell death involves genes whose protein products govern
apoptosis and do not elicit an immune reaction. Once transcribed, these proteins may
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promote cell survival or cause cell death (Desai and Gruber, 1999).
Cell death may also occur by necrosis. As mentioned earlier, the morphological
characteristics of apoptosis include cell shrinkage, maintenance of intact organelles, and
nuclear fragmentation (Thomson, 1998). Necrosis, however, entails the dilation of cells,
destruction of most organelles, perforation of the plasma membrane, and relatively minor
nuclear morphological changes (Thomson, 1998; Wyllie, 1981). Necrosis also occurs in
groups of cells and produces infl ammation (Levin, 1998). Whereas apoptosis is affected
by environmental and physiological elements (Gottlieb and Babior, 1997), necrosis is
provoked by a variety of non-physiological conditions, such as hypothermia, hypoxia,
toxins, autolysis, and the inhibition of glycolysis and the tricarboxylic acid cycle (Wyllie,
1981).
There are instances where the morphological events of cell death fail to fit into
the dichotomy of apoptosis and necrosis. Recently, it was suggested that 'oncosis' or
cytoplasmic swelling and karyolysis, be instituted to characterize cell death. In this
model, necrosis embodies all cell death and may be 'oncotic necrosis' if cells swell, or
'apoptotic necrosis' if cells shrink (Levin, 1998; Majno and Joris, 1996).
The purpose of this study is to examine specific regulatory elements associated
with apoptosis in the Nb2 cell line by employing a morphological approach that
implements immunocytochemistry. The Nb2 cell line was shown to be sensitive to both
pro and anti-apoptotic hormonal signals (Fletcher-Chiappini et al., 1993; Witorsch et al.,
1993; LaVoie and Witorsch, 1995). This property allowed us to study the modulation of
apoptosis.
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The Nb2 cell line was obtained from lymphomas generated in estrogen treated
male Nb rats. The cells were derived from thymocytes at an immature stage of
development (Fleming et al., 1982). Thus, they share characteristics with the normal rat
thymus, such as a large nucleus and nucleolus, sparse endoplasmic reticulum and Golgi
bodies, and a higher volume of log phase cells than stationary cells (Fleming et al., 1982;
Hwang et al., 1974). Nb2 cells appeared to be double positive (CD4/CD8), since they
possessed early antigenic determinants of helper T cells and non-helper T cells. (Fleming
et al., 1982). In T cell maturation, immature thymocytes express both markers, while
differentiated thymic cells contain either marker. Accordingly, the double positive Nb2
cells were likely frozen in an early stage of development.
Nb2 cells are dependent on a lactogenic hormone, such as prolactin, for
mitogenesis (Noble et al., 1985). Incubation in a lactogen free medium for 24 hours
synchronizes approximately 90% of cells in GofG, (Lavoie and Witorsch, 1995).
Administering Prl to synchronized cells restores log phase growth (Krumenacker et al.,
1998; Richards et al., 1982). Nb2 cells were also observed to be sensitive to
glucocorticoids such as Dex. In the absence of mitogen, Dex caused apoptosis of log
phase Nb2 cells after 12-24 hours of exposure. In the presence of Prl, Dex was
antiproliferative although apoptosis did not occur (Fletcher-Chiappini et al., 1993).
Further studies indicated that Prl inhibited Dex-induced apoptosis in a specific dose
dependent manner (Fletcher-Chiappini et al., 1993).
The phenomenon of Dex-induced apoptosis in Nb2 cells and its inhibition by Prl
provides a model for studying the signaling involved in the regulation of programmed
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cell death. In 1995, Lavoie and Witorsch detectedDNA fragmentation in synchronized
Nb2 cells after 4 hours ofDex treatment. Recently, the Tdt-dependent dNTP-biotin Nick
End Labeling (TUNEL) assay was implemented in our laboratory as a morphological,
rather than a biochemical means to detectDNA fragmentation. Guanzon (1998) detected
apoptosis after 6 or 8 hours ofDex treatment in synchronized Nb2 cells using the
TUNEL assay. We intended to identify the signals involved inDex mediated apoptosis
of synchronized Nb2 cells by examining any changes in the levels or distribution of pro
and anti-apoptotic proteins inDex treated cells at time points within this 8 hour time
interval. The fluctuation in the level of a protein prior to apoptosis would suggest that
the signal may be involved in mediating cell death. Our experimental design consisted of
an immunocytochemical examination of specific signals (Fas, Fas Ligand, Bcl-2, Bax,
and p53) in synchronized Nb2 cells that had been exposed toDex for a duration ofO, 1,
2, 4, 6, and 8 hours.
The cascade of events leading to apoptosis is highly conserved and involves all of
the signaling proteins under consideration (Figure 1). In mammals, a pivotal event in the
apoptotic cascade is the release of cytochrome c from the mitochondria. Cytochrome c
activates apoptosis activating factor-1 (Apaf-1), which subsequently activates and
recruits caspase-9 (Adams and Cory, 1998). In general terms, caspases are specific
proteases that either regulate the activity of other caspases or proteins, or directly cause
apoptosis by cleavage of specific proteins (ie. structural and regulatory proteins).
Caspase-9 and Caspase-8 are thought to be involved in the regulation of other caspases
that cause cell death (Thornberry and Lazebnik, 1998). Bcl-2 and Bax effect apoptosis
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by regulating the release of cytochrome c and the activation of Apaf-1 and caspase-9.
Occupation of the Fas receptor causes apoptosis mainly through its interaction with Fasassociating protein with death domain (FADD) and with caspase-8 (which appears to be
independent of the caspase-9 pathway). Lastly, p53 may cause apoptosis by stimulating
Bax or Fas, and by repressingBcl-2. Elements of the apoptotic cascade integrate
opposing pro-apoptotic and anti-apoptotic signals to determine if cell death is required
(Adams and Cory, 1998).

p53

lBCL-2

+

<==BAX

lCYTOCHROME C

<==
+

-<--

p53

l+
BAX

FAS

l+
FADD

RELEASE

l+
APAF-1

l+
CASPASE-9

l+
CASPASE-8

l+
APOPTOSIS

l+
APOPTOSIS

Figure 1. Apoptotic Pathway Involving Fas, Fas Ligand, Bcl-2, Bax, and p53.
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Fas and Fas Ligand are involved in the regulation of apoptosis in many cell types.
Fas, or AP0-1, is a member of the tumor necrosis factor/nerve growth factor receptor
family (Laytragoon-Lewin, 1998; Ohm et a!., 1992), and is found in the liver, kidney,
heart, thymocytes, and B lymphocytes. The binding of the Fas receptor to Fas Ligand
activates Fas, which induces cell death. The Fas protein is comprised of several
specialized regions including extracellular, intracellular, transmembrane, and 'death'
domains. The death domain consists of a conserved sequence of amino acids that plays a
key role in evoking cell death. The initial event in Pas-mediated apoptosis is the
association between Fas and Fas Ligand. This interaction causes the death domain of Fas
to self-interact as a result of 'clustering', which enables Fas to activate FADD (Boldin et
a!., 1995). Subsequently, FADD activates caspase-8, which induces apoptosis (Adams
and Cory, 1998; Gottlieb and Babior, 1997; Chappell and Restifo, 1998).
Fas Ligand is a 45kDa glycoprotein, and a member of theTNF family (Gottlieb
and Babior, 1997). This protein is mainly expressed on activatedT cells, natural killer
cells, Sertoli cells of the testes, and in the eye (Chappell and Restifo, 1998; French et a!.,
1996; Griffith et a!., 1995). In certain instances, mettaloproteases cleave Fas Ligand into
a 26 kDa soluble form of the protein (Chappell and Restifo, 1998; Kayagaki et a!., 1995;
Gottlieb and Babior, 1997).
The binding of Fas Ligand to Fas stimulates apoptosis in various cell types. In
tolerance development ofT cells, the adherence of an immatureT cell receptor with self
antigen results in increased synthesis of both Fas and Fas ligand, inducing cell death
(Ogasawara et a!., 1995; Gottlieb and Babior, 1997). Indeed, when either Fas or Fas
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Ligand is inactivated by mutation in mice, immature T cells are retained and autoimmune
diseases may develop (Ogasawara et al., 1995). In addition, natural killer cells and
cytotoxic T lymphocytes display the Fas Ligand and kill virally infected cells expressing
Fas. Ironically, it is this upregulation of Fas by HIV infected CD4 cells that causes many
lymphocytes to die, hastening the progression of AIDS (Gottlieb and Babior, 1997;
Katsikis et al., 1995). Fas and Fas Ligand also evoke apoptosis as downstream effectors
of other signals like c-Myc and p53 (Chappell and Restifo, 1998; French et al., 1996;
Green, 1997; Hueber et al., 1997). For instance, cytotoxic drugs and irradiation activate
p53, which in tum stimulates Fas mediated apoptosis (Chappell and Restifo, 1998;
Friesen et al., 1996; Reap et al., 1997; Muller et al., 1997).
Bcl-2 and Bax, homologous members of the Bcl-2 family, also play an interactive
role in mediating apoptosis. The Bcl-2 family is comprised of several proteins that
function either as inducers, or as inhibitors of apoptosis (Gottlieb and Babior, 1997). The
function of each member is dependent upon the conserved amino acid sequence, or
domain, that they possess (Adams and Cory, 1998). Of the pro-apoptotic Bcl-2 family
members, the presence of the Bcl-2 homology domain 3 is crucial for evoking cell death
(Adams and Cory, 1998; Conradt et al., 1998; Chittenden et al., 1995). Anti-apoptotic
proteins of the Bcl-2 family require the Bcl-2 homology domain 1 and the Bcl-2
homology domain 2 (Adams and Cory, 1998). The Bcl-2 protein proper is a 26 kDa
protein associated with mitochondrial membrane, nuclear membrane, and endoplasmic
reticulum (Gottlieb, et al., 1997). Bcl-2 protects against apoptosis, chiefly in lymphoid
derived cells (Gottlieb and Babior, 1997). For example, an overexpression of Bcl-2 in
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transgenic mice resulted in increased lymphoid follicles (Gottlieb and Babior, 1997;
Sentman et al., 1991).
Bax is a 21 kDa protein that causes apoptosis (Gottlieb and Babior, 1997). The
Bax protein is widely distributed throughout the body and exists in higher concentrations
in cells with rapid turnover rates such as the colonic epithelium (Gottlieb and Babior,
1997). Upon self-dimerization, Bax induces apoptosis (Gottlieb and Babior, 1997) by
releasing cytochrome c from the mitochondria (Chappell and Restifo, 1998). Bcl-2,
however, separates the Bax homodimer and forms a Bcl-2:Bax dimer (Gottlieb and
Babior, 1997). The Bcl-2 protein is thought to prevent apoptosis by inhibiting caspases
by means of blocking cytochrome c release or binding to Apaf-1 (Lincz, 1998). The
relative concentrations of Bax and Bcl-2 determine whether apoptosis is suppressed by
Bcl-2 or promoted by the Bax homodimer.
In response to DNA damage, a cell may arrest growth, evoke cell death, or repair
altered DNA (Evan and Littlewood, 1998). If a cell sustains significant DNA damage, it
is often prudent to terminate the cell rather than risk its potential for neoplastic growth.
The p53 protein is responsible for causing apoptosis or growth arrest in cells containing
DNA damage. Cells with altered p53 genes have a diminished capacity to curtail cell
growth, and they often proliferate uncontrollably as a neoplastic growth (Jensen et al.,
1997). Hence, the loss of p53 function is associated with a large number of cancers
(Evan and Littlewood, 1998).
In order for p53 to regulate cell proliferation, it must first be separated from its
associated repressor protein, Mdm2. This separation is achieved through the
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phosphorylation of p53 or Mdm-2 by a group of protein kinases (Evan and Littlewood,
1998). Once separated from Mdrn2, p53 is active and capable of inducing apoptosis or
growth arrest (Evan and Littlewood, 1998). Depending on the environment, cell type,
and other signals, either growth arrest or apoptosis is favored (Evan and Littlewood,
1998). Oftentimes, as in the case of glucocorticoid mediated apoptosis, arrest in the G1
phase of the cell cycle precedes apoptosis (King and Cidlowski, 1998).
It is thought that p53 causes apoptosis by repressing the anti-apoptotic protein
Bcl-2, stimulating pro-apoptotic signals such as Bax and Fas (King and Cidlowski, 1998;
Miyashita et al., 1994; Owen-Schaub et al., 1995), or by interacting with IGF1 (Evan and
Littlewood, 1998; Thornberry and Lazebnik, 1998) Alternatively, the process of growth
arrest involves p53-induced transcription of the cyclin dependent kinase inhibitor p21,
which arrests cells in the G1 phase (King and Cidlowski, 1998; Dulic et al., 1994; El
Deiry et al., 1993).
In summary, the primary objective of this study has been to elucidate the roles of
specific signaling proteins (Fas, Fas Ligand, Bcl-2, Bax, and p53) in apoptosis using a
morphophysiological approach. Initially, we attempted to establish the existence and
specificity of these cellular signals by immunostaining and immunoabsorption. Then, we
attempted to quantitate these signals over an 8 hour period following Dex exposure. In
doing so, we hoped to appraise the feasibility of a morphologically based approach for
examining the physiological control of apoptosis.

Chapter 2
Materials And Methods

2.1 Hormones, Antibodies, and Antigens
Dexamethasone ( 1,4 pregnadiene-9fluor-16a-methyl- l l �,17a,21-triol-3,20-dione)
was acquired from Sigma Chemical Co., St. Louis, MO. The Antibodies for Fas, Fas
ligand, Bcl-2, Bax, and p53 were obtained from Santa Cruz Biotechnology Inc., Santa
Cruz, CA. Glutathione agarose, the p53 fusion protein, and antigens corresponding to the
antibodies for Fas, Fas ligand, Bcl-2, Bax, and p53 were also acquired from Santa Cruz
Biotechnology Incorporated. Ovine prolactin (oPrl s-15) was donated by the National
Hormone and Pituitary Program.
Primary antibodies to Fas, Fas ligand, Bcl-2, Bax, and p53 (N-19) were affinity
purified polyclonal antibodies raised against a specific region of a protein. Anti-p53 (FL393), however, was raised against the entire p53 antigen. According to specifications
provided by the supplier, the antibodies to Fas Ligand, Bcl-2, Bax, and p53 (FL-393)
reacted to antigens of rat, mouse, and human origin, whereas anti-Fas reacted to antigens
of mouse and rat origin, and anti-p53 (N-19) reacted to p53 of human origin. Antibodies
for the above proteins were diluted in PBS-.1%BSA to concentrations that exhibited
optimal staining and absorption. In particular, anti-Fas, anti-Fas ligand, and anti-p53
12
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were diluted to 2!J.g/ml, while anti-bax and anti-bcl-2 were diluted to l !J.g/ml. Anti-Fas
(M-20) is directed against a peptide corresponding to amino acids 308-327 of the carboxy
terminus of the Fas precursor of mouse origin. Anti-Fas ligand (N-20) was raised against
a peptide coinciding with amino acids 2-19 at the amino terminus of Fas ligand of rat
origin. Anti-p53 (FL-393) is directed against a fusion protein corresponding to amino
acids 1-393 of p53 protein of human origin (the precise location of the immunoreactive
site is not specified). Anti-p53 (N-19) was raised against a protein coinciding with amino
acids 2-20 of the amino terminus of p53 protein of human origin. Anti-Bcl-2 (N-19) is
directed against a peptide corresponding to amino acids 4-21 at the amino terminus of
Bcl-2 of human origin. Finally, anti Bax (1-19) binds to a protein coinciding with amino
acids 80-98 at the carboxy terminus of Bax of human origin. (Santa Cruz Biotechnology
Inc., 1997)

2.2 Maintenance of Nb2 Lymphoma Cells

The cultured, prolactin dependent Nb2 cells were obtained from Dr. Robert Adler
of the McGuire Veteran's Hospital. Dr. Peter Gout of the Department of Cancer

-

Endocrinology of the British Columbia Cancer Agency was the initial supplier of the
°
cells (Nb2 clone U-17). The Nb2 cells were resurrected from storage at -70 C and
sustained in Fischer's Maintenance Media (FMM), consisting of Fischer's Media
supplemented with 50 units/ml Penicillin, 50!J.g/ml Streptomycin, .075% NaHC03, 10%
Horse Serum, 10% Fetal Calf Serum, and O.lmM P-Mercaptoethanol. Culture flasks
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used in splitting and reculturing cells were Falcon brand 50 rnl. polystyrene flasks with
0.2um vented blue plug seal caps. �-mercaptoethanol was obtained from the Sigma
Chemical Company, while the remaining reagents were purchased from Gibco Life
Technologies, Grand Island, NY. Cultures were incubated in a water-saturated
°
atmosphere of 5% COz and 95% room air at 37 C. The cell count was determined by
Trypan Blue exclusion using a hemacytometer, and cells were recultured twice a week at
5
5
a concentration of 0.5 x 10 - 1.0 x 10 cells/rnl. Nb2 cells were periodically frozen (in
FMM

+

0.8% DMSO) when the cell viability was at least 90% and the concentration of

cells reached 1.0 x 10

6

cells/mi.

2.3 Dexamethasone Cytolytic Assay and Dex-Prl Coincubation Assay

Assays were conducted to determine the cytolytic response of Nb2 cells to Dex
treatment after 24 hours (chronic) and at discrete time points (acute). Furthermore, the
effects of Prl on Nb2 Cells was examined by the Dex-Prl coincubation assay.
For the acute Dex cytolytic assay, cells were first synchronized in Go/GJ. Cell
synchronization was achieved in the following manner: when cells reached a
6
concentration of approximately 0.5-0.75 x 10 cells/rnl in FMM, they were centrifuged
°
twice at 1000 rpm for 5 minutes at 8-10 C and washed twice in chemically defined,
serum-free synthetic medium (SYN), consisting of .1mM �-mercaptoethanol, 50 units/rnl
Penicillin, 50 Jlg/rnl Streptomycin 0.15% (wtlvol), Bovine serum albumin, 4Jlg/ml
Linoleic acid, 1mM Sodium pyruvate, 12 Jlg/rnl Transferrin, 15ng/rnl Selenium, 1x

15
vitamins (diluted from a commercial stock of 100x), 0.33x amino acids (diluted from a
commercial stock of 100x), 0.5mM CaCh, and 0.15mM Hepes (dissolved in Fischer's
medium). The cell concentration was then adjusted to 500,000 cells/rnl in SYN, and cells
°
were incubated at 37 C for 24 hours. After this 24 hour incubation in SYN,
approximately 90% of cells enter into Go/G1 (Lavoie and Witorsch, 1995). Synchronized
cells were washed twice in Fischer's Medium and cells were counted with a
hemacytometer. From the washed cells, cell concentration was adjusted to 2.0 x 10

6

cells/rnl in SYN and plated at 3ml/well in Costar brand 6-well plates. Then, 1.25 �l/ml of
DMSO and 80nM Dex in DMSO were added to the cell suspensions. Cells were
incubated with Dex or vehicle for 0, 1, 2, 4, 6, and 8 hours. Following each time point,
cells were harvested and percent viability per well was determined with a hemacytometer
by counting living and dead cells (those cells that do not exclude Trypan Blue) in
triplicate. Previous studies have indicated that three counts are required to achieve
reliable cell quantitation (Fletcher-Chiappini et al., 1993). After each time point, cells
were also fixed to slides for immunocytochemical studies.
In the chronic cytolytic assay, cells were tested for their responsiveness to
Dex±Prl following a 24 hour incubation period using a 4 well design. Log phase- cells in
°
FMM were centrifuged twice at 1000 rpm for 5 minutes at 8-10 C and washed twice in
SYN. The cells were then reconstituted in SYN and counted by Trypan Blue exclusion
using a hemacytometer. The concentration of cells was then adjusted to approximately
6
0.5 x 10 cells/rnl (at a volume of 1.5rnl in SYN) containing one of the following 4
treatments: Control (0.125% DMSO), Dex (100nM Dex in 0.125% DMSO), Dex

+

Prl

16
( l OOnM Dex in 0.125% DMSO, 1ng/ml oPrl S-15), and Prl (1ng/ml oPrl S-15, 0.125%
DMSO). All incubations occurred at 37° C in a 5% C02 incubator for 24 hours, at which
time percent viability per well was determined by Trypan Blue exclusion as described
above.

2.4 Cell Fixation

Cell fixation methods remained constant for synchronized, log phase, treated, and
untreated cells. A total of 3 x106 cells were obtained from a cell suspension by
determining the cell concentration and acquiring the necessary volume. These cells were
centrifuged at 1000 rpm for 5 minutes in an Eppendorf microcentrifuge at room
temperature. Following aspiration of supernatant, the cells were resuspended in 3.7%
formaldehyde in .01M PBS (pH 7.1) for ten minutes at room temperature. The stock
formaldehyde (37%) was diluted in .01M PBS to a concentration of 3.7%, and was
allowed to reach room temperature prior to cell fixation. After fixation, cells were
recentrifuged at 1000 rpm for 5 minutes, the supernatant was aspirated, and the remaining
pellet was resuspended in 750 Jll .O l M PBS (pH 7.0). Approximately 12 Jll of fixed cells
were added to an etched circle (5mm in diameter) on Fischer Super-Frost Plus slides, and
allowed to dry at room temperature.

2.5 Immunocytochemistry (ICC)
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ICC was used to localize antigens within cells with primary antibodies directed
against signaling proteins. In this process, samples on slides were first hydrated in .OlM
PBS for 5 minutes. Fixed cells were hydrated directly by immersion of the slide in PBS.
Paraffin sections, however, were deparaffinized by immersion in xylene, a series of
alcohols (100% Ethanol, 95% Ethanol, 70%Ethanol, 50%Ethanol), and finally ddH20.
Once deparaffinized, the section was hydrated as above. Pituitary sections embedded in
paraffin were used as positive controls in ICC experiments. The antibody added to
control sections was rabbit anti-canine Prl at concentrations of 1:1600, 1:3200, 1:6400,
and 1:12,800.
Following hydration of samples, specific reagents were added sequentially as
drops, and then incubated in an airtight, humidified chamber at room temperature for
specified time periods. In between the addition of each reagent, slides were flooded with
10rnl of 0.01M PBS. The first reagent added was 0.2% Triton+ PBS for 30 minutes,
which permeabilized the section. Blocking solution was then added for 20 minutes.
Subsequently, primary antibody was added and allowed to incubate for 3 hours (as
mentioned earlier, dilutions of antibodies ranged from 1-2 �-tg/ml, and were based on the
staining observed in pilot experiments). Then, biotinylated secondary antibody (i2.5%
solution) was added for 30 minutes. Next, ABC solution (20%) was added to the sample
for 30 minutes. The slides were then inserted into a coplin jar filled with Aldrich brand
Diaminobenzidine (DAB) in solution (12.5 mg DAB/50rnl of .05M tris HCl at pH 7.6)
plus 50�-tl of pharmaceutical grade 3% H202 for a duration of 10 minutes. Following this
incubation, the slides were immersed in tap water and dehydrated by insertion into
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ddHzO, a series of alcohols (50% ethanol, 70% ethanol, 95% ethanol, 100% ethanol), and
lastly, xylene. Finally, coverslips were applied to slides using Pro-Tex mounting
medium.
The Vectastain Universal Elite ABC kit was utilized to localize antibody bound to
antigen (this kit recognized antibodies generated in rabbits and mice). In this procedure,
the chromagenic substrate (DAB) binds to an avidin/biotinylated peroxidase complex
(ABC), which itself is attached to a biotinylated antibody:primary antibody:protein
complex. (Vector Laboratories, Inc., 1996). Vectastain solutions (blocking serum,
biotinylated antibody, and ABC) were prepared as recommended in the kit instructions.

2.6 Antibody Absorption

The specificity of antibody-induced staining in cells was examined through
immunoabsorption. This involved creating mixtures of antibody with the antigen that
was used for its generation. In most cases, the antigen used for absorption was a peptide
of about 20 amino acids corresponding either to the N-terrninus or C-terrninus of the
molecule. The rationale for immunoabsorption is that if the antigen binds to the
immunoreactive site on the antibody, or epitope, it would prevent binding of the antibody
to the antigen within the fixed specimen, hence precluding staining. In the
immunoabsorption of Fas, Fas ligand, Bcl-2, and Bax, antibodies were incubated with
their respective antigens at a ratio of 10:1 (peptide to antibody), which was the ratio
recommended by the supplier, for 24 hours at 4° C. To achieve a 10:1 ratio of peptide to
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antibody, a volume of 10

f.tl of peptide (200

flg/ml) was added to 100 fll of working stock

antibody (2 flg/ml). The control consisted of 10 fll of PBS -.02% BSA added to 100 fll
working stock antibody (2 flg/ml) incubated as above. Absorbed and control solutions
were applied to slides of fixed log phase cells. The absence of staining after exposure to
the antibody/peptide solution signified absorption of that antibody by peptide, and hence
verified specificity of imrnunostaining (Witorsch, 1980). As presented in the results, we
were able to conclusively demonstrate imrnunoabsorption for anti-Fas, anti-Fas Ligand,
anti-Bcl-2, and anti-Bax.
While the absorption of anti-Fas, anti-Fas Ligand, anti-Bcl2, and anti-Bax were
straightforward, establishing the specificity of p53 imrnunostaining was more complex.
To our knowledge, a rabbit antibody directed against the N or C terminus of p53 was not
available with its corresponding antigen. However, goat antibody directed against the N
terminus (amino acids 2-20) or the C terminus (373-391) of p53 was available with its
respective peptide from Santa Cruz Biotechnology. Unfortunately, we were unable to
obtain successful imrnunostaining using an antibody generated in a goat (N-19) while
employing a Santa Cruz ABC kit capable of detecting goat antibodies (the Vector
Universal ABC kit detects rabbit and mouse antibodies). A rabbit antibody directed
against the entire human p53 molecule (FL-393) was available from Santa Cruz, which
yielded excellent staining (intense staining with low background) using the Vector
Universal ABC kit. The mixture of this antibody with peptides directed against the C
terminus (amino acids 2-20) and N terminus (amino acids 373-391) together failed to
diminish staining of anti p53 (FL-393). Other attempts at absorption involved using a

20
glutathione-S-transferase (GST) fusion protein containing the entire human p53 molecule
(amino acids 1-393) as the absorption agent. This protein, which was the original antigen
used to generate FL-393, consisted of p53 (53kDa) and GST (27 kDa). When the weight
of the GST is factored into the calculation, the ratio of antigen to antibody is 15:1 in
order to obtain the appropriate ratio of antigen to antibody of 10:1. The mixture of antip53 (FL-393) with the fusion protein (I-393) failed to establish immunospecificity of p53
immunostaining, even when the N-terrninus (N-19) and C-terrninus (R-19) were also
added. Finally, attempts at removing the anti-p53/p53 GST complex from solution by the
addition of glutathione agarose (Santa Cruz) followed by centrifugation also failed to
satisfactorily establish immunospecificity.
2.7 Photomicography

Photomicography of cells of ICC experiments was achieved by using a Nikon
Optiphot photomicography system and Kodak Ektachrome ISO 100 slide film. To attain
an accurate representation of cells stained, four fields of cells in each etched circle were
photagraphed at approximately 2, 4, 8, and 10 o'clock relative to the circle. Objective
magnification was at either 20X or 40X for best visualization of immunostaining. Less
intensely stained cells and sparse cell fields called for the higher magnification.
Photographs were taken toward the center of the circle since central cells demonstrated
more representative staining than peripheral cells, and were less subject to high
background staining, or 'edge artifact'. Fields containing significant cell clumping,
debris, or other artifacts were avoided.

21

2.8 Data Processing
Photomicography as described above yielded approximately 100 cells per field.
Processing of these cell fields was accomplished by slide scanning, cell quantitation, and
statistical analysis. The developed Ektachrome slides were first scanned into TIFF files
by one of three methods: Sprint Scan, Nikon SF-200, or Artec Scanrom 4E. Cell
quantitation was primarily achieved by use of Scion Image software (Scion Corp,
Frederick, Maryland), which was downloaded from the Internet at www.scioncorp.com.
This software allowed for computerized counting of total cells and stained cells in digital
images. Each scanned image was opened in greyscale and the total number of cells was
determined by altering the threshold value of the image so that only the boundaries of
cells were visible. By choosing the "Analyze Particles" function, cellular outlines were
counted. To determine the number of stained cells, the threshold of each image was
lowered to the point where cellular outlines disappeared and stained inclusions remained.
In this case, the "Analyze Particles" function counted only the visible inclusions of
stained cells. Some manual data processing was required due to incompatibilities of
certain images with Scion Image software. In this case, the number of total cells and
stained cells were counted visually from an image opened on Corel Photo Paint-8.
Additionally, for the p53 ICC experiments, nuclear and cytoplasmic localization was
examined visually.
ICC experiments on the proteins of interest were performed in triplicate. Data
from these three experiments were used for statistical analysis using Sigma Stat 2.0
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software. First, means and standard errors were calculated. Then, Kruskal-Wallis one
way ANOV A on ranks compared differences between treatments over the 8 hour time
period. Cytolytic data were compared by the Duncan's multiple range tests.

Chapter 3
Results

3.1 Effect of Dex and PrJ on cell viability in non-synchronized Nb2 lymphoma cells.

Figure 2 depicts a typical cell viability response of log phase Nb2 cells after 24
hours of exposure to Dex

±

Prl. Trypan Blue exclusion was employed to quantitate cell

viability. Dex causes a 7-fold increase in the percentage of dead cells compared to
DMSO treatment, bringing the proportion of dead cells to about 50 percent.
Coincubation with Prl protects cells against Dex induced cytolysis.

3.2 Effects of Dex on viability of synchronized Nb2 lymphoma cells.

Table 1 shows the percentages of dead cells after Dex treatment for 0, 1, 2, 4, 6,
and 8 hours in synchronized (Go/01) Nb2 cells. A significant increase in dead cells was
observed after 6 and 8 hours of Dex exposure. Cytolytic data also suggested the
possibility of spontaneous cell death since the percentage of dead cells after 8 hours of
DMSO exposure (14.7%) was significantly different from the proportions of dead cells at
-24 hours (2% dead) and at 0 hours (4% dead). The percentages of apoptotic cells were
23
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measured in the same Nb2 cells by the TUNEL assay (Guanzon, 1998). There is a
significant increase in the proportion of apoptotic cells after 8 hours of Dex treatment.

3.3 Immunocytochemistry and antibody absorption

Figures 3-7 illustrate immunocytochemical staining for Fas, Pas-ligand, Bcl-2,
Bax, and p53. All of the antibodies mentioned produced characteristic staining in log
phase Nb2 lymphoma cells (Fig. 3A-6A, 7). In particular, Fas appeared to be localized to
the cell surface and periphery of most cells (Figure 3A). Fas Ligand staining was most
evident in the periphery of cells, although some cells appeared centrally stained (Figure
4A). Staining for Bcl-2 was most apparent toward the periphery of cells, while some
cells were centrally stained (Figure SA). Bax staining was characterized by both
peripherally and centrally stained cells (Figure 6A). Finally, p53 exhibited
predominantly peripheral staining (Figure 7). The immunospecificity of Fas, Fas Ligand,
Bcl-2, and Bax staining was verified by their disappearance when the antibody was
absorbed by admixture with its corresponding peptide antigen (3B-6B). As discussed in
the methods section, the specificity of anti-p53 immunostaining by immunoabsoiption
could not be verified.

3.4 Examination of antibody staining in response to DMSO and DEX treatments of
various time periods.
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Tables 2-6 display the percentages of cells stained for Pas, Pas Ligand, Bcl-2,
Bax, and p53 after DMSO and DEX treatment for 0, 1, 2, 4, 6, and 8 hours. Since p53
has been implicated in nuclear translocation, nuclear localization was also examined for
this protein. For each of the antibodies under consideration, the percentages of log phase
cells that were stained ranged from 72% to 86%. Among these antibodies, there were no
statistically significant differences in the proportions of cells stained between log phase
cells and synchronized cells. In addition, we failed to detect any statistically significant
changes in the percentages of stained cells between Dex and DMSO treatments over 8
hours. No obvious redistribution in staining (periphery to central) was evident for p53.
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Fig 2. Cell viability of non-synchronized Nb2 lymphoma cells following
24 hour Dex ± Prl co-incubation.
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Table 1. Response of Synchronized Nb2 Lymphoma Cells to DMSO and DEX exposure
after 0, 1, 2, 4, 6, and 8 Hour Time Periods.
Percent Dead Cells
Time (Hours)

Treatment

-24

Log phase

0

Synchronized

1

2

4

6

8

as Measured by
Trypan Blue Exclusion

Percent Apoptotic

Cells as Measured by
TUNEL Assayd

2.0±1.0

5.7±1.5

4.0±0.6

11.0±3.2
10.7±3.2

DMSO

8.2±1.6

DEX

9.9±1.6

DMSO

7.7±2.3

DEX

6.0±1.7

10.7±3.5

8.0±1.5

DMSO

10.7±0.3

DEX

9.3±4.1

10.2±0.9

11.3±3.5

12.0±4.5

DMSO

10.0±.0.6

10.3±1.2

DEX

17.7±0.9b

15.0±1.2

DMSO

14.7±1S

10.0±2.3

DEX

21.0±2.83

20.0±2.13

Values are Mean ± SEM; n=3
a

Difference is significant at p!>0.05 vs. 0 hour, all DMSO controls and 1, 2, 4, and 6 hour

Dex treatments.
b Difference is significant at p!>0.05 vs. 0 hour, 1, 2 , 4, and 6 hour DMSO controls and 1,
2, and 4 hour Dex treatments.
c

Difference is significant at p!>0.05 vs. 0 hour, -24 hour (log phase), all DMSO controls,

and 1, 2, 4, and 6 hour Dex treatments.
d Data obtained by Guanzon (1998).
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Table 2. Proportion of Cells Stained for Anti-Fas in ICC Experiments in Nb2 Lymphoma
Cells after DMSO and Dex Treatment of Various Time Periods.

Percent Cells
Stained for
Time (Hours)

Treatment

Anti-Fas

-24

Log Phase

71.7±5.7

0

Synchronized

70.0±5.0

1

DMSO

71.3±6.7

Dex

82.0±3.2

DMSO

75.3±2.0

Dex

80.3±5.0

DMSO

76.0±4.2

Dex

76.0±4.1

DMSO

72.3±2.9

Dex

77.7±4.3

DMSO

70.5±1.5

Dex

78.3±3.8

2

4

6

8

(Mean ± SEM, n=3)
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Table 3. Proportion of Cells Stained for Anti-Fas Ligand in ICC Experiments in Nb2
Lymphoma Cells after DMSO and Dex Treatment of Various Time Periods.

Percent Cells
Stained for
Time (Hours)

Treatment

-24

Log Phase

79.0±7.6

0

Synchronized

80.0±2.9

DMSO

84.3±0.9

Dex

88.0±3.8

DMSO

84.7±1.5

Dex

84.0±2.3

2

4

6

8

Anti-Fas Ligand (Mean ± SEM)

DMSO

81.0±3.2

Dex

85.3±1.9

DMSO

82.7±2.9

Dex

85.3±3.3

DMSO

75.7±1.9

Dex

83.0±2.7
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Tab le4. Proportion of Cells Stained for Anti-Bcl-2 in ICC Experiments in Nb2
Lymphoma Cells after DMSO and Dex Treatment of Various Time Periods.

Percent Cells
Stained for
Time (Hours)

Treatment

Anti-Bcl-2

-24

Log Phas e

76.3±3.0

0

Synchronized

74.7±2.2

1

DMSO

76.0±3.2

Dex

80.0±1.0

DMSO

70.7±5.4

Dex

78.7±5.0

2

4

6

8

DMSO

72.3±1.5

Dex

73.7±1.8

DMSO

55.7±10.9

Dex

64.7±15.4

DMSO

56.0±15.3

Dex

53.7±13.1

(Mean± SEM, n=3)
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Table 5. Proportion of Cells Stained for Anti-Bax in ICC Experiments in Nb2
Lymphoma Cells after DMSO and Dex Treatment of Various Time Periods.

Percent Cells
Stained for
Time (Hours)

Treatment

Anti-Bax

-24

Log Phase

86.3±3.0

0

Synchronized

73.7±6.6

1

DMSO

80.3±2.3

Dex

72.3±10.0

DMSO

84.0±1.0

Dex

78.0±6.5

DMSO

85.3±1.8

Dex

82.7±3.5

2

4

6

8

DMSO

86.3±1.3

Dex

82.3±2.3

DMSO

81.7±2.9

Dex

80.7±.9

(Mean ± SEM, n=3)
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Table 6. Proportion of Cells Stained for Anti-p53 in ICC Experiments in Nb2
Lymphoma Cells after DMSO and Dex Treatment of Various Time Periods.

Percent Cells
Stained for
Time (Hours)

Treatment

Anti-p53(Mean ± SEM, n=3)

-24

Log Phase

73.3±3.7

0

Synchronized 79.3±1.3

1

2

4

6

8

DMSO

79.7±2.9

Dex

82.3±1.5

DMSO

77.0±7.1

Dex

81.7±3.5

DMSO

79.0±5.0

Dex

79.0±2.5

DMSO

81.7±2.0

Dex

79.7±2.9

DMSO

71.0±4.4

Dex

70.0±5.5
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Figure 3. A illustrates immunocytochemical staining for Fas in log phase Nb2 lymphoma
cells. Antibody was at a concentration of2j.ig/ml. B reveals the disappearance of
staining following absorption of antibody with its antigen. Antigen concentration was at
20j.ig/ml. Magnification x354.
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Figure 4. A illustrates immunocytochemical staining for Fas Ligand in log phase Nb2
lymphoma cells. Antibody was at a concentration of21J.g/ml. B reveals the
disappearance of staining following absorption of antibody with its antigen. Antigen
concentration was at 201J.g/ml. Magnification x354.
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Figure 5. A illustrates immunocytochemical staining for Bcl-2 in log phase Nb2
lymphoma cells. Antibody was at a concentration of 1 J.lg/ml. B reveals the
disappearance of staining following absorption of antibody with its antigen. Antigen
concentration was at I Of.lg/ml. Magnification x354.
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Figure 6. A illustrates immunocytochemical staining for Bax in log phase Nb2
lymphoma cells. Antibody was at a concentration of I f,lg/ml. B reveals the
disappearance of staining following absorption of antibody with its antigen. Antigen
concentration was at I Oflg/ml. Magnification x354.
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Figure 7. Demonstration of immunocytochemical staining for p53 in log phase Nb2
lymphoma cells. Antibody was at a concentration of 2�-tg/ml. Magnification x354.
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Chapter 4
Discussion

The purpose of this study has been to elucidate the mechanisms of apoptosis
control in Nb2 lymphoma cells. By employing morphological techniques, we intended to
visualize signaling proteins (Fas, Fas Ligand, Bcl-2, Bax, and p53) associated with
apoptosis, and to establish the specificity of antibodies directed against these signals
through irnrnunoabsorption of the antibodies with their corresponding peptides. We
investigated the role of these signaling proteins in apoptosis by visualizing and
quantitating them in synchronized Nb2 cells over an 8 hour time period following Dex
exposure.
The Nb2 cells we used in our experiments responded in a typical manner to
Dex±Prl exposure; Dex caused an increase in the percentage of dead cells over DMSO
levels, and coincubation of Prl with Dex protected cells against Dex-induced cytolysis.
This response is concordant with the results obtained from previous studies by Fletcher
Chiappini et al. (1993) and by Guanzon (1998). Since this typical response provides a
model for studying the signaling involved in apoptosis, we were able to utilize these cells
for further studies.
By using ICC, we intended to determine the feasibility of a morphological
43
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approach for investigating apoptosis control. This approach was selected because it
appeared to confer numerous advantages over the traditional biochemical techniques of
Western blots and agarose gel electrophoresis. Biochemical methods require a
homogenate of the cell population to extract pooled protein or DNA. Through
immunohistochemistry, however, one can analyze single cells with preserved cellular
architecture (Gavrielli et al., 1992). Furthermore, a maintained cell structure affords the
opportunity to observe localization of staining within cells, and the ability to compare
staining under varying treatments and at different time points. Examining qualitative
aspects of cells in this manner would appear to offer much insight into the role of
signaling proteins involved in apoptosis. In addition, ICC on intact cells may allow for
simultaneous localization of signaling proteins.
Through ICC, we were able to localize Fas, Fas ligand, Bcl-2, Bax, and p53 in
Nb2 cells. The antibodies for Fas, Fas ligand, Bcl-2, and Bax were affinity-purified
rabbit polyclonal antibodies raised against a specific amino acid sequence at theN
terminus or C-turminus of the protein. The specificity of immunostaining for these 4
antibodies was verified by their disappearance when the antibodies were mixed with the
peptides that were used to initially generate the antibodies.
The localization of p53 by ICC required the use of a rabbit polyclonal antibody
directed against the entire p53 protein (in fact, the original antigen was a p53Glutathione-S-transferase fusion protein). We were unable to eliminate immunostaining
produced by this antibody despite using several distinct approaches. For example, the
addition of the p53 GST fusion protein and the peptide sequences corresponding to the
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N-terminus (amino acids 2-20) and C-terminus (373-391) of p53 failed to eliminate
immunostaining. Additionally, attempts at removing the anti-p53/p53GST complex by
adsorption to agarose beads containing glutathione failed to prevent immunostaining.
The failure to verify the immunospecificity of p53 may be due to several reasons. First
of all, cell fixation may have altered the immunoreactive site of cellular p53, causing it to
have a higher affinity for the anti-p53 antibody than the exogenous protein added during
absorption. Secondly, the configuration of the immunoreactive site(s) on p53 may have
been modifie� by its fusion to GST, consequently making it (them) inaccessible to the
antibody. In addition, to our knowledge, the p53 GST fusion protein has never been used
as an immunoabsorbant (according to consultation with Santa Cruz Biotechnology), and
thus may act in an atypical manner. Third, the anti-p53 we used may not react with the C
or N-terminus of p53 protein. Fourth, anti-p53 may be binding in a non-specific manner
to another antigen, cellular protein, or an artifact of the cellular preparation. In other
words, the staining may not be specific for p53. The failure to demonstrate
immunospecificity of p53 signifies that its visualization can not be affirmed with
certainty. Although immunoabsorption of an antibody with its antigen measures
antibody specificity and antigen localization (Witorsch, 1980), many researchers fail to
absorb their antibodies, and they may be visualizing something other than their targeted
protein. In fact, numerous studies have reported to stain for p53 by ICC without using
absorption controls, such as the visualization of p53 in breast carcinomas (Jensen et a!.,
1997), the localization of p53 in mammary epithelial cells (Delmolino et a!., 1993), and
the staining of p53 in tumors derived from transgenic mice (Hall et a!., 1998).
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Previously, immunocytochemical data that were generated in our laboratory were
quantitated manually. The visual counting of hundreds of fields of cells became the rate
determining step of data analysis. In the present study, we have implemented a novel,
computerized means to quantitate the total number of cells, as well as the number of
stained cells per field, using Scion Image software. This methodology offers a more
objective, consistent, and expeditious means of cell quantitation versus non-computerized
quantitation. Currently, we have been able to utilize the image analysis software to count
the proportion of stained cells in a given field. We may potentially be able to use this
software to determine the distribution of cell staining (ie. nuclear, cytoplasmic, or cell
surface localization) and to measure the intensity of cellular staining.
While computer-assisted cell quantitation has yielded more accurate cell counts,
we have become increasingly aware of sources of imprecision in our methodology.
When cells were counted in a hemacytometer by Trypan Blue exclusion, a single cell
count could vary as much as 40% from another cell count (unpublished observations is
our laboratory). After empirical testing, we came to the conclusion that multiple (at least

3) aliquots of the same cell suspension should be utilized for quantitation in order to
achieve a cell count within 10% of the actual cell concentration (from unpublished
observations in our laboratory). By photographing and counting 4 fields of cells per
etched circle, we quantitated staining for a single aliquot of a cell suspension. To
minimize this variability in cell quantitation (in accordance with our hemacytometer
findings), at least 3 aliquots of each cell suspension would have to each be photographed
and counted as described above.
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The proportions of log phase cells that were stained for Fas, Fas Ligand, Bcl-2,
Bax, and p53 ranged from 72% to 86%. Using the same Nb2 cells, Guanzon (1998)
found approximately40% of log phase cells to be positively stained for Glucocorticoid
receptor (GR), IkBA, NFkB, and STAT-5b. The discrepancy in the proportions of
stained cells for different signals in Nb2 cells suggests the following: High percentages
(72-86%) of cells stained for Fas, Fas Ligand, Bcl-2, Bax, and p53 indicate that the
majority of Nb2 cells contain all of these signals. A lower percentage (40%) of cells
stained for GR, IlcBA, NFkB and STAT-5b suggests that there may be a single subset of
,

cells positive for all4 signals, or several subsets of cells that each contain one or more of
these proteins. To resolve these issues, we are currently examining the simultaneous
localization of these signals in Nb2 cells.
Immunocytochemical experiments staining for Fas and Fas Ligand in log phase
Nb2 cells revealed that 72% of cells contained Fas, while 79% of cells expressed Fas
Ligand, indicating that both proteins are within the same cell in the majority of the cell
population. Generally, the binding of Fas Ligand to Fas receptor induces cell death by
apoptosis (Laytragoon-Lewin, 1998). It is intriguing that although Fas and Fas ligand are
both present in Nb2 cells, Fas mediated apoptosis is absent, indicated by a continually
high (>90%) cell viability. There are several possible explanations for the resistance of
Nb2 cells to Fas mediated apoptosis. First, Fas and Fas ligand association is not always
fatal, and depends on the presence of specific elements that regulate the cell's response;
these elements cause significant variability of cellular responses to Fas and Fas ligand
association. (Gottlieb and Babior, 1997). For example, while both macrophages and
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endothelial cells express Fas, only macrophages undergo apoptosis in response to Fas
ligand (Gottlieb and Babior, 1997; Richardson et al., 1994). In some instances, Fas
occupation may even causeT cell proliferation (Gottlieb and Babior, 1997; Agarwal et
al., 1995).
Next, the stage of development ofT cells determines the cellular response to Fas
and Fas Ligand binding. InT lymphocyte development, immature cells possess both the
CD4 (helperT cell) marker and the CD8 (cytotoxicT lymphocyte) marker. As cells
mature, T cells express only the CD4 or CD8 marker. Double positive, immatureT cells
are sensitive to Fas mediated apoptosis, whereas more mature, single positiveT cells are
resistant to apoptosis (Ogasawara et al., 1995). The Nb2 lymphoma cell line was shown
to be positive for both markers, suggesting that they would be susceptible to Fas induced
cell death (Fleming et al., 1982). The resistance to Fas mediated apoptosis may have
been mediated by discrete signals downstream from Fas and Fas Ligand binding.
Furthermore, the Nb2 cells that we utilized may have changed through time from the
initial clone, resulting in a single positive (CD4 or CD8) phenotype that has become
resistant to Fas induced apoptosis. Additionally, studies from Fleming et al. (1982)
suggested that Nb2 cells were double positive (CD4/CD8), because monoclonal
antibodies (W3/25-HLK and OX8-HL) bound to early antigenic determinants of helperT
cells and nonhelperT cells. It may be prudent to reevaluate the markers in Nb2 cells
using more current methodology.
Finally, overexpression of the transcription factor Bcl-2 has been found to
partially block Fas mediated apoptosis (Nagata et al., 1995; Itoh et al., 1993). Since we
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observed most log phase cells (76%) to be positive for Bcl-2, overexpressed Bcl-2 may
explain the low occurrence of cell death in Fas and Fas ligand positive Nb2 cells.
Furthermore, when Bcl-2 associates with its binding protein, BAG-I, Fas mediated
apoptosis is completely inhibited (Nagata et al., I995; Takayama et al., I995). Further
studies testing for the BAG-I protein would verify or disqualify this phenomenon in Nb2
cells.
The p53 protein is usually found in low levels due to its association with MdM2,
which inactivates p53 (Admas et al., I998). However, we observed p53 to be detectible
by ICC in a majority (73%) of untreated log phase cells. The elevated p53 levels may be
due to the presence of mutated p53 or upregulated, wild type p53. Since the viability of
Nb2 cells remained over 90%, the p53 was probably not the wild type, which would
evoke cell death and decrease this viability substantially. Hence, the p53 we localized by
ICC in Nb2 cells was most likely in its mutated (inactive) form.
It was observed that glucocorticoids induce apoptosis in immature thymocytes by
p53 independent mechanisms (Macfarlaine et al., I996). If this is accurate in Nb2
lymphoma cells, then Dex treatment would not effect p53 levels. The independence of
p53 and Dex induction of apoptosis may explain why we observed no statistiCally
significant changes in the percentages of stained cells for p53 over the 8 hour Dex time
course assay.
Using immunoblot analysis, Krumenacker et al. (I998) demonstrated that there
were no changes in the levels of Bcl-2 or Bax protein in stationary Nb2 cells that had
been treated with Dex for I2 hours. Our results have corroborated this finding; we found
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no statistically significant changes in the percentages of stained cells for Bcl-2 or for Bax
over the 8 hour Dex time point assay.
Cytolysis was observed in synchronized Nb2 cells after 6 and 8 hours of Dex
exposure using Trypan Blue exclusion counts. This cytolytic response was correlated to
the occurrence of apoptosis at 8 hours, as measured by the TUNEL assay (Guanzon, M.S.
thesis, 1998). Presumably, Dex-induced cytolysis was caused by apoptosis. There was
also a possibility of spontaneous cytolysis, since the percentages of dead cells rose from
2% at -24 hours and 4% at 0 hours to 14.7% after 8 hours of DMSO exposure (this type
of cell death was not validated by the TUNEL assay, however ). In previous studies
(Lavoie and Witorsch, 1995), DNA fragmentation caused by apoptosis was observed in
synchronized Nb2 cells after 4 hours of Dex exposure by the Diphenylamine assay and
agarose gel electrophoresis. The morphologically based TUNEL assay and Trypan Blue
exclusion counts appeared to have detected apoptosis at a later time than biochemical
means detected apoptosis for the following reasons: The Nb2 subline we were using may
have changed through time from the original cells after multiple generations.
Consequently, these modified cells may have responded to Dex in a delayed fashion. On
the other hand, our results indicate that log phase cells responded to Dex±Prl in the
typical fashion, suggesting that these cells were not modified. Alternatively, Guanzon
(1998) found that a relatively small proportion (40%) of cells expressed GRand
underwent apoptosis due to Dex exposure. Hence, detectibility of the response may have
been diminished by the high proportion of non-responsive cells. Finally, the possible
occurrence of spontaneous cytolysis in Nb2 cells could delay the observation of the Dex
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response.
Since the irnmunostaining for all antibodies except p53 was found to be specific,
the lack of any significant changes in the proportion of stained cells would suggest the
independence of these signals in response to synchrony and Dex treatment. In the case of
Bcl-2 and Bax, this is consistent with the finding of Krumenacker et al. (1998), that no
changes in the levels of bcl-2 or bax protein were observed (using immunoblot analysis)
in response to Dex in Nb2 cells. Additionally, our findings appear to be consistent with
those of MacFarlaine et al. (1996), that glucocorticoid induction of apoptosis in immature
thymocytes does not involve p53. Alternatively, the inability to demonstrate changes in
signals may reflect limitations in the methodology in its present stage.
As indicated previously, there may be more variability in the quantitation of ICC
experiments than we anticipated. While we performed ICC experiments in triplicate and
photographed 4 fields per treatment, we utilized only one aliquot of cells per time point
when spotting cells for the Dex time course assay. Quantitation of 3 aliqouts per time
point would have reduced this variability. Furthermore, refinements may have to be
implemented in order to visualize the changes in intensity of immunostaining (ie. titration
of antibody) and the possible intracellular redistribution of signals (ie. counterstaining or
ultrastructural analysis).
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